**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 66743

**Manuscript Type:** MINIREVIEWS

**Dengue hemorrhagic fever and cardiac involvement**

Leowattana W *et al*. Dengue hemorrhagic fever and cardiac involvement

Wattana Leowattana, Tawithep Leowattana

**Wattana Leowattana,** Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

**Tawithep Leowattana,** Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand

**Author contributions:** Leowattana W wrote the paper; Leowattana T collected the data.

**Corresponding author: Wattana Leowattana, BSc, MD, MSc, PhD, Associate Professor, Senior Researcher, Staff Physician,** Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th

**Received:** April 4, 2021

**Revised:** May 30, 2021

**Accepted:** July 7, 2021

**Published online:** June 28, 2021

**Abstract**

Dengue viral infection (DVI) is one of the world’s most significant viral infections spreading. Most of the patients have been asymptomatic, with relatively benign clinical manifestations and outcomes. However, a small number of patients have progressed to severe dengue diseases, including hemorrhage, multi-organ impairment, and increased vascular leakage causing hypovolemic shock, which can cause cardiovascular collapse and death. Numerous lines of evidence have demonstrated that DVI could also cause cardiac dysfunction, arrhythmias, and severe myocarditis. The treatment for dengue hemorrhagic fever (DHF) patients remains symptomatic and supportive, with close monitoring of hemodynamic status. The contributory role of cardiac dysfunction in DHF patients has potentially critical implications on the management. This review will address the current knowledge of cardiac involvement in DHF patients and the management strategy to reduce the fatality outcome.

**Key Words:** Dengue hemorrhagic fever; Dengue viral infection; Cardiac involvement; Cardiac injury; Myocarditis; Left ventricular ejection fraction; Tachycardia; Bradycardia; Electrocardiography; Echocardiography; Severe dengue disease

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Leowattana W, Leowattana T. Dengue hemorrhagic fever and cardiac involvement. *World J Meta-Anal* 2021; 9(3): 286-296

URL: https://www.wjgnet.com/2308-3840/full/v9/i3/286.htm

DOI: https://dx.doi.org/10.13105/wjma.v9.i3.286

**Core Tip:** The majority of dengue virus infections (DVIs) are mild; only a small number of the patients develop overt complications and fatal outcomes. Dengue can also have cardiac involvement, including myocardial dysfunction, cardiac rhythm abnormality, and myocarditis which can implicate severe dengue disease and dengue shock syndrome. Fulminant dengue myocarditis has evidence of extensive cardiomyocyte infection and damage, with an abnormality of electrocardiography, echocardiography, and accompanied by elevated cardiac markers. Early recognition of cardiac involvement in DVI patients, intravascular fluid replacement, circulatory overload monitoring, and preparing the essential tools for critical management are crucial in dengue hemorrhagic fever patients with cardiac involvement.

**INTRODUCTION**

Dengue viral infection (DVI) is a worldwide arthropod-borne disease that has rapidly spread throughout the tropics, with the highest risk zones in Asia and the Americas[1,2]. More than 3 billion people are living in the Aedes-infested areas and at risk of DVI[3]. Asia accounts for 75% of the DVI burden, followed by Latin America and Africa. The most significant vector *Aedes aegypti* is a daytime mosquito, capable of stinging many people in a short period of time and breeding in several types of human-made containers with water inside[4].

Dengue virus (DENV) is an enveloped virus with a single positive-stranded RNA genome, belonging to the genus *Flavivirus* of the family *Flaviviridae*. There are four distinct serotypes, designated as DENV-1, DENV-2, DENV-3, and DENV-4. The viral RNA encodes three structural proteins, namely capsid (C), pre-membrane, and envelope (E), and seven non-structural (NS) proteins, namely NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5[5-7]. The incubation period of DVI is 3-7 d, and the symptoms start abruptly, following three sequential phases—an initial febrile phase, a critical phase, and a spontaneous recovery phase. The febrile phase's pathognomonic features include acute onset of high-grade fever with chill, severe malaise, vomiting, and constitutional symptoms. The critical phase is characterized by varying degrees of plasma leakage into the pleural and abdominal cavities, which causes intravascular volume depletion and might progress to life-threatening dengue shock syndrome (DSS)[8]. Moreover, hemorrhagic manifestations commonly occur during the critical phase. The most common causes of death include bleeding into major vital organs, massive bleeding, and shock. The pathophysiology of shock is poorly understood and has been described as intravascular fluid loss due to increased capillary permeability and bleeding. Organ impairment occurs during this phase, as a hepatic dysfunction with elevated aminotransferase enzymes, cardiac dysfunction with myocardial injury, and a broad range of rhythm disturbances[9,10]. The recovery phase is characterized by a sudden arrest of the plasma leaks, with concomitant reabsorption of extravasated plasma and fluids. Furthermore, DENV and the NS1 are detected in blood circulation during acute DVI, and high viral load or NS1 antigenemia have been demonstrated with severe dengue diseases (SDDs), particularly in secondary infection with different serotype from the primary infection[11,12].

Viral infection of the heart is relatively common in DVI and usually of small consequence. However, it can lead to substantial myocarditis and severe acute heart failure. Acute myocarditis can present in various clinical manifestations (Table 1). The most common viruses known to cause myocarditis are shown in Figure 1. DENV is one of the viral infections of the heart. Although the human immunodeficiency virus and coxsackie B virus are important causes of myocarditis, an extensive review including them is beyond the scope of this article. Cardiac involvement in DVI is a typical intricacy, especially in a large-scale hospital setting with many dengue hemorrhagic fever (DHF) patients, and may be a contributing factor in the pathogenesis of shock and may influence the clinical outcome. Clinical features of cardiac involvement from DENV can vary widely, from asymptomatic to severe cardiac failure, which has a high fatality rate[13,14].

In 1967, Bhamarapravati *et al*[15] first reported the hearts’ pathological sections from 100 DHF autopsy cases. They found that 42 of 100 patients (42%) who died from DHF had focal areas of hemorrhage in the epicardium, sub-endocardium, interstitial tissues, or a combination of such. The most common finding was the separation of myocardial fibers with interstitial tissue edema. Hemorrhage in the myocardium was extensive, with condensation and an acidophilic pattern of myocardial fibrils. There were also a few cases of interstitial infiltration by a small number of mononuclear and lymphoid cells. Moreover, several investigators have demonstrated that cardiac involvement in DVI might cause death in DHF patients[16–20]. However, clinical practice guidelines (CPGs) have only slightly addressed cardiac involvement as a mandatory concern in DHF management[21,22]. Recently, the CPG from the Pan American Health Organization included myocarditis as a crucial pathophysiologic factor in SDD[23].

This review presents the incidence, clinical manifestation, electrocardiogram (ECG) abnormalities, cardiac biomarkers, echocardiography (ECHO), and cardiac imaging in DVI patients with cardiac involvement.

**INCIDENCE AND CLINICAL MANIFESTATION**

In 1998, Wali *et al*[24] conducted a study to evaluate cardiac involvement in 17 consecutive patients with DHF, by use of radionuclide ventriculography, ECHO, and ECG during the epidemic of DEN-2. They found that the mean left ventricular (LV) ejection fraction (LVEF) was 41.69%, and 7 patients (41.17%) had LVEF < 40%. Moreover, global hypokinesia was detected in 12 patients (70.59%) and was found to revert to normal within 3 wk. They concluded that acute reversible cardiac involvement was present in DHF or DSS and could be responsible for clinical shock. Hence, the role of ECG, ECHO, and radionuclide ventriculography in the clinical evaluation of DHF and DSS patients should be considered tools to improve the prognosis in these patients.

In the same year, Kabra *et al*[25] conducted a study to evaluate cardiac involvement in 54 pediatric patients admitted to the hospital with various grades of DVI (DF/DHF/DSS). They found that 9/54 (16.7%) children had LVEF < 50% and 2/54 (3.70%) had LVEF < 35%. They concluded that cardiac functions need to be assessed in patients with DVI, especially those with hypotension, with adequate hydration. In 2003, Khongphatthanayothin *et al*[26] reported an observational study of LV performance and hemodynamic abnormalities during different stages of DHF. They found that LVEF and velocity of circumferential fiber shortening adjusted for end-systolic meridional wall stress and end-diastolic volume were significantly lower during the toxic stage than after recovery. Moreover, the cardiac index was found to be low during the toxic stage and to remain subnormal during the convalescence stage due to sinus bradycardia. They concluded that the mechanism of decreased cardiac output during a toxic stage in DHF patients was complex, due to decreased preload, decreased LV performance, and subnormal heart rate response (Table 2).

In 2007, Kularatne *et al*[27] investigated cardiac complications in 120 DHF patients between 13-76 years of age. They found that 75/120 (62.5%) of the patients had ECG abnormalities (*e.g*., T inversion, ST depression, bundle branch blocks). Moreover, 5/75 (6.66%) of the patients had LVEF < 55%. They concluded that cardiac involvement in DHF was common and early recognition and differentiation from DSS is crucial. In the same year, Khongphatthanayothin *et al*[28] conducted a study to determine the prevalence of myocardial depression and its effect on the clinical severity in 91 patients with DF, DHF, and DSS. They found that during the critical stage, LVEF < 50% was present in 2 (6.7%), 5 (13.8%) and 9 (36.0%) patients with DF, DHF and DSS, respectively. Furthermore, all 14 patients in convalescent stage who had had LVEF < 50% at the critical stage presented LVEF ≥ 50%. They concluded that the proportion of patients with cardiac dysfunction was larger for those with higher clinical severity of the disease.

In 2009, Salgado *et al*[29] conducted a prospective study to determine the incidence of myocarditis in 102 DHF children. They found that 11/102 (10.7%) of the children had signs of myocarditis, 10/102 (9.8%) needed inotropic drugs, 9/102 (8.8%) had bradyarrhythmias, and 2/102 (1.9%) had tachyarrhythmias. Investigations by ECHO demonstrated pericardial leakage in 2/102 (1.96%) and diminished LVEF in 1/102 (0.98%) of the patients. They concluded that the myocarditis in DHF patients was not rare and should be of concern during DHF management. In 2011, La-Orkhun *et al*[30] evaluated the cardiac arrhythmias and heart rate variability in 35 children with DVI using overnight 18-24-h Holter monitoring. They found that 10/35 (29%) of the patients had cardiac rhythm abnormalities [sinus pause, first-degree arterioventricular (AV) block, Mobitz type I second-degree AV block (Wenckebach), atrial ectopic beats, and ventricular ectopic beats] during the convalescent stage. There was no association between the clinical severity and the incidence of cardiac arrhythmia. They concluded that various benign bradyarrhythmias and ectopic beats are present in patients with DVI during the convalescent stage.

One year later, Yacoub *et al*[18] conducted an observational study to evaluate the cardiac involvement in 79 DVI patients (age range of 8-46 years). They found that the patients with severe dengue had worse cardiac function than those with dengue, in the form of LV systolic dysfunction and with increased left myocardial performance index. Furthermore, septal myocardial systolic velocities (S′) were also reduced. They concluded that the patients with severe dengue have evidence of systolic and diastolic cardiac impairments, with the septal and right ventricular wall being predominantly affected. Then, in 2013, Miranda *et al*[31] conducted a study to evaluate the cardiac involvement in 81 DVI patients. They found that 12/81 (14.81%) of the patients had elevated troponin I and NTproBNP. Of the 10 patients, 1 showed reduced LVEF, 2 showed LV segmental abnormalities with preserved ejection fraction, and 1 showed a significant pericardial effusion with tamponade; cardiac magnetic resonance confirmed cardiac dysfunction in these 4 patients. They concluded that the heart could be affected by DENV in a considerable percentage of patients needing hospitalization. Overall, these date indicate that clinical presentations range from mild elevation of cardiac markers to myocarditis and pericarditis. These cardiac dysfunctions might be underdiagnosed in clinical practice and contribute to the high mortality rates of DHF and DSS.

Later on, Sengupta *et al*[32] conducted a prospective study that used 2D ECHO images of the LV in the four-, three- and two-chamber views and parasternal short-axis views at the basal, mid and apical levels to evaluate 40 participants (20 DHF, and 20 controls). They found that LV global ejection fraction was reduced in patients with DHF at presentation, as compared with controls. The peak longitudinal strain in patients with DHF was significantly attenuated in the subendocardial region, as compared with that in normal controls. DHF patients showed significantly higher radial strain than controls. They concluded that the identification of reduced LV longitudinal strain helps in understanding the mechanism of reduced LV myocardial performance seen in patients with DHF.

Yadav *et al*[33] conducted a study to evaluate myocardial involvement in infants and children with severe dengue using the Tei index, which combines systolic and diastolic time intervals to assess global ventricular function. They found fewer patients with severe dengue had myocardial involvement on admission by LVEF (48%) than by the Tei index (70%). They concluded that most of the patients with severe dengue had asymptomatic myocarditis, as evident by a deranged Tei index, which improved but did not normalize by the time of discharge. Hence, these groups of patients needed a longer follow-up period.

In 2015, Kirawittaya *et al*[34] conducted a study to characterize the incidence and changes in cardiac function by serial ECHO in 181 DF and DHF patients compared with 35 non-dengue patients. They found that DHF patients who developed plasma leakage had lower cardiac index (2695 *vs* 3188 L/min/m2*,* *P* = 0.003) and higher LV myocardial performance index (0.413 *vs* 0.328, *P* = 0.021) and systemic vascular resistance (2478 *vs* 1820 dynes.s/cm-5*,* *P* = 0.005) compared to those without plasma leakage. Moreover, cardiac dysfunction was most pronounced around the time of plasma leakage. They concluded that transient LV systolic and diastolic dysfunction was common in pediatric DHF patients and related to the severity of plasma leakage.

In the same year, Li *et al*[35] conducted a study to investigate the prevalence of myocarditis using ECG, ECHO, and cardiac enzymes tests in 1782 DHF patients. They found that 201/1782 (11.28%) of the patients had myocarditis. Moreover, the prevalence of myocarditis in non-severe dengue with warning signs and severe dengue was 46.66% compared with non-severe dengue without warning signs, which was 9.72%. DHF patients with myocarditis experienced longer hospitalization than those without myocarditis (7.17 ± 4.64 *vs* 5.98 ± 2.69, *P* = 0.008). They concluded that the incidence of myocarditis increased with the severity of DHF; moreover, the prognosis of DHF patients with and without myocarditis had no significant difference, even if myocarditis patients experienced longer hospital stay.

In 2020, Bhatt *et al*[16] conducted a prospective observational study to evaluate the cardiac involvement among 182 admitted DHF patients of age ≥ 14 years. They found that 44/182 (24%) of the DHF patients demonstrated some ECG abnormalities, such as sinus tachycardia, sinus bradycardia, and non-specific ST changes. Moreover, cardiac markers were elevated in 27/182 (14.8%) of the DHF patients, and among these patients, 11/27 (40.7%) had ECHO evidence of myocarditis. The incidence of myocarditis in that study was 7.10%. The authors concluded that myocarditis among admitted dengue patients is not uncommon and may cause increased morbidity and mortality. Thus, there is a need to have a CPG to diagnose and treat myocarditis among DHF patients.

Bhattacharjee *et al*[36] conducted a study to compare cardiac markers in DF patients with and without myocarditis. The patients were classified as cases (ECG and ECHO changes of LVEF < 50%; *n* = 41) and controls (age and sex-matched with normal ECG and ECHO; *n* = 43). They found that creatine kinase (CK), CK-MB, troponin T, and NT-proBNP concentrations were higher in the cases than in the controls. Serum troponin T and NT-proBNP were also found to be positively correlated to each other. They concluded that routine monitoring of cardiac markers, in conjunction with ECG and ECHO in early diagnosis and management of myocarditis, was needed for DVI patients.

In 2021, Cabrera-Rego *et al*[37] conducted a study to characterize the cardiovascular manifestations in 427 hospitalized patients with DVI. They found that 19.7% of these patients had cardiovascular manifestations. The manifestations were, specifically, sinus bradycardia (13.8%), atrial extrasystoles (4.9%), and ventricular extrasystoles (4.0%). Pericarditis and myocarditis were detected in 1.6% and 0.2%, respectively. The higher probability of presenting cardiac dysfunctions in DVI patients was decreased platelet count [odds ratio (OR = 1.13)], advanced age (OR = 1.70), male sex (OR = 1.94), and dengue with warning signs (OR = 3.29). They concluded that cardiovascular signs in patients with dengue are common and self-limited. It is essential to consider these findings and not underestimate cases with asymptomatic pericarditis or myocarditis.

Shah *et al*[38] conducted a study to evaluate the incidence and spectrum of cardiac abnormalities in 320 patients with DF. They found that 112/320 (35%) of DF patients had changes of cardiac manifestations, with 19.7% having sinus bradycardia, 13.1% having LVEF < 40%, 15% having elevated troponin T, 10.6% having elevated CK-MB, and 5.9% having elevated NTproBNP. The mortality rate was 4.38% among the entire patient population that presented cardiac involvement. They concluded that cardiac dysfunction in patients with DVI was common. Moreover, their findings showed that the abnormalities of ECG, ECHO, and cardiac markers were predictors of risk for adverse outcomes.

**HISTOPATHOLOGICAL FINDINGS**

An extensive series of histopathological findings regarding DHF patients were reported since 1967[15]. In 1968, Burke[39] reported the autopsy findings of 12 DHF cases, all of which had cardiac involvement, including epicardial petechial hemorrhage, myocardium focal hemorrhage, and subendocardial hemorrhage in the posterior wall of the LV. Moreover, the author stated having not found evidence of myocarditis with normal blood vessels. In 2011, Weerakoon *et al*[20] reported that 5 autopsy DSS patients' histopathological findings showed evidence of florid myocarditis; the distinct histological findings of the myocardium were interstitial edema with inflammatory cell infiltration, necrosis of myocardial fibers, and evidence of pericarditis. They concluded that primary cardiac failure due to myocarditis in DHF is usually overlooked.

Management guidelines for DHF should address myocarditis as an important issue. The primary histopathological features are shown in Table 3[15,20,39-42]. Moreover, DENV antigen has been detected with immunohistochemistry in fatal dengue with clinical myocarditis[13,20,31,43,44]. Myocardial damage had also been demonstrated in patients dying of dengue[20,45]. Weerakoon *et al*[20] showed severe myocardial damage with hemorrhage, interstitial edema with inflammatory cell infiltration, and necrosis of myocardial fibers. Moreover, Torres *et al*[46] demonstrated focal and diffuse myocarditis with cellular infiltration by lymphocytes, neutrophils, and eosinophils in the patients who died from dengue. Pericarditis, characterized by chest pain, has also been demonstrated in histopathology of DHF patients’ autopsies[20,47]. This evidence may suggest that direct viral-induced cardiac tissue damage does take place.

**PATHOPHYSIOLOGY OF CARDIAC DYSFUNCTION IN DENGUE**

Although the exact mechanisms leading to cardiac dysfunction in DVI are not clearly understood, two mechanisms of cardiac injury may cause it, either directly (*via* DENV invasion and damage to the cardiac tissues) or indirectly (*via* cytokine-induced immune damage), or both may be at play[20,48]. Numerous inflammatory mediators, such as cytokines, tumor necrosis factor-α, interleukins [(ILs), *e.g*., IL-1, IL-2, IL-6, IL-13, and IL-18] and cytotoxic factors, as well as increased capillary permeability, may play a vital role in the pathogenesis of cardiac dysfunction[49-51].

Cardiac dysfunction in DVI, although mild and self-limited, can be caused by SDD, which results in progressive and intractable acute heart failure with global hypokinesia and acute cardiac dilatation[24,28,29]. After DENV enters the body, it will be attacked by macrophages, which in turn causes T cell activation. Activated T cells then release several inflammatory mediators and induce the complement system pathways’ activation (*i.e*. C3a and C5a). This process will cause inflammation and necrosis of the endothelial cell lining of blood vessels, leading to increased capillary permeability and vascular leakage. When the vascular leakage occurs in myocyte interstitial spaces, it will cause myocardial interstitial edema, leading to the impairment of myocardial contraction and reduced overall function. Moreover, intravascular blood volume decreases, leading to coronary circulation impairment. The release of numerous cytokine mediators also affects cardiac electrical conduction and suppresses cardiac contractility, leading to conduction block and arrhythmias. Another factor that may contribute to cardiac dysfunction in DHF patients is a derangement of calcium ion storage in the myocytes, directly leading to myocarditis[13,52,53].

**MANAGEMENT**

Cardiac dysfunction in DHF is primarily asymptomatic and transient, and there are no specific guidelines available for its management. Thus, routine ECG will provide clear evidence of myocarditis or abnormal cardiac rhythm in this group of patients. The patients who have abnormal ECG with clinical manifestations of cardiac involvement should be progressed to ECHO evaluation. The most critical problem has been determining whether myocarditis is playing a contributory role in a patient with shock. The goal of the management is to provide symptomatic and supportive care to maintain hemodynamic stability. These goals include maintenance of optimal intravascular volume, with use of diuretics and inotropic drugs as necessary. Moreover, special care should be taken not to cause iatrogenic fluid overload[54,55].

Corticosteroid treatment in SDD with myocarditis remains controversial. Only one study to date has shown rapid recovery of a child with myocarditis upon intravenous administration of methylprednisolone[56]. Tachyarrhythmias, including atrial fibrillation (AF), have also been documented in patients with dengue but are much less common than bradyarrhythmias. A few studies have supported the use of anti-arrhythmic drugs in non-self-limiting AF[57-59]; although, the CPG has still not been clearly defined. However, the efficacy of channel blockers and β-blockers for AF treatment caused by DVI is not conclusive because of co-existing hypotension. Notably, close and regular monitoring of the clinical presentation of DHF patients is crucial. Furthermore, a vigorous treatment regimen to maintain normal hemodynamic stability is the critical point of DHF patient management.

**CONCLUSION**

Cardiac dysfunction has been reported to be more severe in patients with DSS than in those with DF or non-shock DHF. The pathophysiology of myocardial damage in DHF patients is not yet fully elucidated. It may result either from direct DENV damage of the cardiomyocytes or an indirect cytokine-mediated immunological response, or even a combined effect. Cardiac involvement in DHF is not uncommon. Although acute, transient and self-limited, acute cardiac dysfunction in DHF may lead to clinically severe state and a fatal outcome. Early detection of cardiac involvement in DVI patients, prompt resuscitation of hemodynamic instability, avoidance of circulatory overload, and sparing the essential tools for critical management are vital in managing DHF patients with severe cardiac dysfunction.

**REFERENCES**

1 **Bhatt S**, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. *Nature* 2013; **496**: 504-507 [PMID: 23563266 DOI: 10.1038/nature12060]

2 **Messina JP**, Brady OJ, Pigott DM, Golding N, Kraemer MU, Scott TW, Wint GR, Smith DL, Hay SI. The many projected futures of dengue. *Nat Rev Microbiol* 2015; **13**: 230-239 [PMID: 25730702 DOI: 10.1038/nrmicro3430]

3 **Kraemer MU**, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG, Carvalho RG, Coelho GE, Van Bortel W, Hendrickx G, Schaffner F, Elyazar IR, Teng HJ, Brady OJ, Messina JP, Pigott DM, Scott TW, Smith DL, Wint GR, Golding N, Hay SI. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. *Elife* 2015; **4**: e08347 [PMID: 26126267 DOI: 10.7554/eLife.08347]

4 **Ogden NH**, Gachon P. Climate change and infectious diseases: What can we expect? *Can Commun Dis Rep* 2019; **45**: 76-80 [PMID: 31285696 DOI: 10.14745/ccdr.v45i04a01]

5 **Wilder-Smith A**, Ooi EE, Horstick O, Wills B. Dengue. *Lancet* 2019; **393**: 350-363 [PMID: 30696575 DOI: 10.1016/S0140-6736(18)32560-1]

6 **Simmons CP**, Farrar JJ, Nguyen VV, Wills B. Dengue. *N Engl J Med* 2012; **366**: 1423-1432 [PMID: 22494122 DOI: 10.1056/NEJMra1110265]

7 **Perera R**, Kuhn RJ. Structural proteomics of dengue virus. *Curr Opin Microbiol* 2008; **11**: 369-377 [PMID: 18644250 DOI: 10.1016/j.mib.2008.06.004]

8 **Rosenberger KD**, Lum L, Alexander N, Junghanss T, Wills B, Jaenisch T; DENCO Clinical Study Group. Vascular leakage in dengue--clinical spectrum and influence of parenteral fluid therapy. *Trop Med Int Health* 2016; **21**: 445-453 [PMID: 26752720 DOI: 10.1111/tmi.12666]

9 **Kye Mon K**, Nontprasert A, Kittitrakul C, Tangkijvanich P, Leowattana W, Poovorawan K. Incidence and Clinical Outcome of Acute Liver Failure Caused by Dengue in a Hospital for Tropical Diseases, Thailand. *Am J Trop Med Hyg* 2016; **95**: 1338-1344 [PMID: 27928082 DOI: 10.4269/ajtmh.16-0374]

10 **Yacoub S**, Wertheim H, Simmons CP, Screaton G, Wills B. Cardiovascular manifestations of the emerging dengue pandemic. *Nat Rev Cardiol* 2014; **11**: 335-345 [PMID: 24710495 DOI: 10.1038/nrcardio.2014.40]

11 **Bhatt P**, Sabeena SP, Varma M, Arunkumar G. Current Understanding of the Pathogenesis of Dengue Virus Infection. *Curr Microbiol* 2021; **78**: 17-32 [PMID: 33231723 DOI: 10.1007/s00284-020-02284-w]

12 **Halstead S**. Recent advances in understanding dengue. *F1000Res* 2019; **8** [PMID: 31448083 DOI: 10.12688/f1000research.19197.1]

13 **Salgado DM**, Eltit JM, Mansfield K, Panqueba C, Castro D, Vega MR, Xhaja K, Schmidt D, Martin KJ, Allen PD, Rodriguez JA, Dinsmore JH, López JR, Bosch I. Heart and skeletal muscle are targets of dengue virus infection. *Pediatr Infect Dis J* 2010; **29**: 238-242 [PMID: 20032806 DOI: 10.1097/INF.0b013e3181bc3c5b]

14 **Caforio AL**, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013; **34**: 2636-2648, 2648a-2648d [PMID: 23824828 DOI: 10.1093/eurheartj/eht210]

15 **Bhamarapravati N**, Tuchinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. *Ann Trop Med Parasitol* 1967; **61**: 500-510 [PMID: 5634140 DOI: 10.1080/00034983.1967.11686519]

16 **Bhatt M**, Soneja M, Farooqui FA, Singla P, Vikram NK, Biswas A, Roy A, Wig N. Myocarditis in admitted patients with dengue fever. *Infection* 2020; **48**: 899-903 [PMID: 32780310 DOI: 10.1007/s15010-020-01500-w]

17 **Buntubatu S**, Prawirohartono EP, Arguni E. Myocarditis Prevalence in Paediatric Dengue Infection: A Prospective Study in Tertiary Hospital in Yogyakarta, Indonesia. *J Trop Pediatr* 2019; **65**: 603-608 [PMID: 31006000 DOI: 10.1093/tropej/fmz020]

18 **Yacoub S**, Griffiths A, Chau TT, Simmons CP, Wills B, Hien TT, Henein M, Farrar J. Cardiac function in Vietnamese patients with different dengue severity grades. *Crit Care Med* 2012; **40**: 477-483 [PMID: 21946658 DOI: 10.1097/CCM.0b013e318232d966]

19 **Zea D,** Foley K, Carey J. Myocarditis in a traveler returning from the Dominican Republic: an unusual presentation of dengue fever. *Am J Trop Med Hyg* 2014; **91:** 156-158 [PMID: 24891462 DOI: 10.4269/ajtmh.13-0637]

20 **Weerakoon KG**, Kularatne SA, Edussuriya DH, Kodikara SK, Gunatilake LP, Pinto VG, Seneviratne AB, Gunasena S. Histopathological diagnosis of myocarditis in a dengue outbreak in Sri Lanka, 2009. *BMC Res Notes* 2011; **4**: 268 [PMID: 21798066 DOI: 10.1186/1756-0500-4-268]

21 **World Health Organization.** Dengue Guidelines for Diagnosis, Treatment, Prevention and Control, New edition 2009. [cited 15 March 2021]. Available from: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf

22 **World Health Organization.** Handbook for Clinical Management of Dengue, 2012. [cited 15 March 2021]. Available from: https://www.who.int/iris/bitstream/10665/76887/1/9789241504713\_eng.pdf

23 **Pan American Health Organization (PAHO).** Dengue: Guidelines for Patient Care in the Region of the Americas, Second edition 2016. [cited 15 March 2021]. Available from: https://iris.paho.org/bitstream/handle/10665.2/31207/9789275118900-eng.pdf

24 **Wali JP**, Biswas A, Chandra S, Malhotra A, Aggarwal P, Handa R, Wig N, Bahl VK. Cardiac involvement in Dengue Haemorrhagic Fever. *Int J Cardiol* 1998; **64**: 31-36 [PMID: 9579814 DOI: 10.1016/s0167-5273(98)00008-4]

25 **Kabra SK**, Juneja R, Madhulika, Jain Y, Singhal T, Dar L, Kothari SS, Broor S. Myocardial dysfunction in children with dengue haemorrhagic fever. *Natl Med J India* 1998; **11**: 59-61 [PMID: 9624863]

26 **Khongphatthanayothin A**, Suesaowalak M, Muangmingsook S, Bhattarakosol P, Pancharoen C. Hemodynamic profiles of patients with dengue hemorrhagic fever during toxic stage: an echocardiographic study. *Intensive Care Med* 2003; **29**: 570-574 [PMID: 12595978 DOI: 10.1007/s00134-003-1671-9]

27 **Kularatne SA**, Pathirage MM, Kumarasiri PV, Gunasena S, Mahindawanse SI. Cardiac complications of a dengue fever outbreak in Sri Lanka, 2005. *Trans R Soc Trop Med Hyg* 2007; **101**: 804-808 [PMID: 17428513 DOI: 10.1016/j.trstmh.2007.02.021]

28 **Khongphatthanayothin A**, Lertsapcharoen P, Supachokchaiwattana P, La-Orkhun V, Khumtonvong A, Boonlarptaveechoke C, Pancharoen C. Myocardial depression in dengue hemorrhagic fever: prevalence and clinical description. *Pediatr Crit Care Med* 2007; **8**: 524-529 [PMID: 17906598 DOI: 10.1097/01.PCC.0000288672.77782.D4]

29 **Salgado DM**, Panqueba CA, Castro D, R Vega M, Rodríguez JA. [Myocarditis in children affected by dengue hemorrhagic fever in a teaching hospital in Colombia]. *Rev Salud Publica (Bogota)* 2009; **11**: 591-600 [PMID: 20169215 DOI: 10.1590/s0124-00642009000400010]

30 **La-Orkhun V**, Supachokchaiwattana P, Lertsapcharoen P, Khongphatthanayothin A. Spectrum of cardiac rhythm abnormalities and heart rate variability during the convalescent stage of dengue virus infection: a Holter study. *Ann Trop Paediatr* 2011; **31**: 123-128 [PMID: 21575316 DOI: 10.1179/1465328111Y.0000000008]

31 **Miranda CH**, Borges Mde C, Matsuno AK, Vilar FC, Gali LG, Volpe GJ, Schmidt A, Pazin-Filho A, Silva FM, Castro-Jorge LA, Oliveira MF, Saggioro F, Martines RB, Fonseca BA. Evaluation of cardiac involvement during dengue viral infection. *Clin Infect Dis* 2013; **57**: 812-819 [PMID: 23784923 DOI: 10.1093/cid/cit403]

32 **Sengupta SP**, Nugurwar A, Jaju R, Khandheria BK. Left ventricular myocardial performance in patients with dengue hemorrhagic fever and thrombocytopenia as assessed by two-dimensional speckle tracking echocardiography. *Indian Heart J* 2013; **65**: 276-282 [PMID: 23809381 DOI: 10.1016/j.ihj.2013.04.017]

33 **Yadav DK**, Choudhary S, Gupta PK, Beniwal MK, Agarwal S, Shukla U, Dubey NK, Sankar J, Kumar P. The Tei index and asymptomatic myocarditis in children with severe dengue. *Pediatr Cardiol* 2013; **34**: 1307-1313 [PMID: 23397334 DOI: 10.1007/s00246-013-0639-y]

34 **Kirawittaya T**, Yoon IK, Wichit S, Green S, Ennis FA, Gibbons RV, Thomas SJ, Rothman AL, Kalayanarooj S, Srikiatkhachorn A. Evaluation of Cardiac Involvement in Children with Dengue by Serial Echocardiographic Studies. *PLoS Negl Trop Dis* 2015; **9**: e0003943 [PMID: 26226658 DOI: 10.1371/journal.pntd.0003943]

35 **Li Y**, Hu Z, Huang Y, Li J, Hong W, Qin Z, Tong Y, Li J, Lv M, Li M, Zheng X, Hu J, Hua J, Zhang F, Xu DL. Characterization of the Myocarditis during the worst outbreak of dengue infection in China. *Medicine (Baltimore)* 2016; **95**: e4051 [PMID: 27399087 DOI: 10.1097/MD.0000000000004051]

36 **Bhattacharjee D,** Choudhury J, Mukherjee K, Mukherjee K. Evaluation of cardiac biomarkers in dengue myocarditis in a tertiary care hospital in eastern India. *J Clin Diag Res* 2020; **14:** BC04-BC08 [DOI: 10.7860/JCDR/2020/46354.14377]

37 **Cabrera-Rego JO**, Rojas-Quiroz AF, Vidal-Turruelles Y, Yanes-Quintana AA. Cardiovascular disorders in hospitalized patients with dengue infection. *Enferm Infecc Microbiol Clin (Engl Ed)* 2021; **39**: 115-118 [PMID: 32345488 DOI: 10.1016/j.eimc.2020.02.032]

38 **Shah C**, Vijayaraghavan G, Kartha CC. Spectrum of cardiac involvement in patients with dengue fever. *Int J Cardiol* 2021; **324**: 180-185 [PMID: 32931859 DOI: 10.1016/j.ijcard.2020.09.034]

39 **Burke T**. Dengue haemorrhagic fever: a pathological study. *Trans R Soc Trop Med Hyg* 1968; **62**: 682-692 [PMID: 5707920 DOI: 10.1016/0035-9203(68)90120-x]

40 **Kularatne SAM**, Rajapakse MM, Ralapanawa U, Waduge R, Pathirage LPMMK, Rajapakse RPVJ. Heart and liver are infected in fatal cases of dengue: three PCR based case studies. *BMC Infect Dis* 2018; **18**: 681 [PMID: 30567553 DOI: 10.1186/s12879-018-3603-x]

41 **Marques N**, Gan VC, Leo YS. Dengue myocarditis in Singapore: two case reports. *Infection* 2013; **41**: 709-714 [PMID: 23277366 DOI: 10.1007/s15010-012-0392-9]

42 **Rathi KR**, Arora MM, Sahai K, Tripathi S, Singh SP, Raman DK, Anand KB. Autopsy findings in fatal dengue haemorrhagic fever - 06 Cases. *Med J Armed Forces India* 2013; **69**: 254-259 [PMID: 24600119 DOI: 10.1016/j.mjafi.2012.08.021]

43 **Guzmán MG**, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L, Cabrera MV, Kourí G. Fatal dengue hemorrhagic fever in Cuba, 1997. *Int J Infect Dis* 1999; **3**: 130-135 [PMID: 10460923 DOI: 10.1016/s1201-9712(99)90033-4]

44 **de Araújo JM**, Schatzmayr HG, de Filippis AM, Dos Santos FB, Cardoso MA, Britto C, Coelho JM, Nogueira RM. A retrospective survey of dengue virus infection in fatal cases from an epidemic in Brazil. *J Virol Methods* 2009; **155**: 34-38 [PMID: 18951921 DOI: 10.1016/j.jviromet.2008.09.023]

45 **Basílio-de-Oliveira CA**, Aguiar GR, Baldanza MS, Barth OM, Eyer-Silva WA, Paes MV. Pathologic study of a fatal case of dengue-3 virus infection in Rio de Janeiro, Brazil. *Braz J Infect Dis* 2005; **9**: 341-347 [PMID: 16270128 DOI: 10.1590/s1413-86702005000400012]

46 **Torres AF**, Braga DN, Muniz F, Mendonça C, Oliveira DN, de Souza ET, Burke A, Tavora F. Lymphocytic myocarditis at autopsy in patients with dengue fever. *Braz J Infect Dis* 2013; **17**: 619-621 [PMID: 24055392 DOI: 10.1016/j.bjid.2013.03.009]

47 **Tayeb B**, Piot C, Roubille F. Acute pericarditis after dengue fever. *Ann Cardiol Angeiol (Paris)* 2011; **60**: 240-242 [PMID: 21664601 DOI: 10.1016/j.ancard.2011.05.008]

48 **Vo HTM**, Duong V, Ly S, Li QZ, Dussart P, Cantaert T. Autoantibody Profiling in Plasma of Dengue Virus-Infected Individuals. *Pathogens* 2020; **9** [PMID: 33352902 DOI: 10.3390/pathogens9121060]

49 **Lee IK**, Lee WH, Liu JW, Yang KD. Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients. *Int J Infect Dis* 2010; **14**: e919-e922 [PMID: 20851651 DOI: 10.1016/j.ijid.2010.06.011]

50 **Shivanthan MC**, Navinan MR, Constantine GR, Rajapakse S. Cardiac involvement in dengue infection. *J Infect Dev Ctries* 2015; **9**: 338-346 [PMID: 25881521 DOI: 10.3855/jidc.6200]

51 **Verhagen LM,** de Groot R. Dengue in children. *J Infect* 2014; **69 Suppl 1:** S77-86 [PMID: 25225163 DOI: 10.1016/j.jinf.2014.07.020]

52 **Sangle SA**, Dasgupta A, Ratnalikar SD, Kulkarni RV. Dengue myositis and myocarditis. *Neurol India* 2010; **58**: 598-599 [PMID: 20739801 DOI: 10.4103/0028-3886.68664]

53 **Shivanthan MC**, Rajapakse S. Dengue and calcium. *Int J Crit Illn Inj Sci* 2014; **4**: 314-316 [PMID: 25625064 DOI: 10.4103/2229-5151.147538]

54 **Seppelt IM**, Orde SR. Why guess when you can see? Heart function and fluid management in dengue shock. *Crit Care Med* 2012; **40**: 675-676 [PMID: 22249046 DOI: 10.1097/CCM.0b013e31823d77e9]

55 **Halstead S**, Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management. *J Travel Med* 2019; **26** [PMID: 31423536 DOI: 10.1093/jtm/taz062]

56 **Premaratna R**, Rodrigo KM, Anuratha A, de Alwis VK, Perera UD, de Silva HJ. Repeated dengue shock syndrome and 'dengue myocarditis' responding dramatically to a single dose of methyl prednisolone. *Int J Infect Dis* 2012; **16**: e565-e569 [PMID: 22521778 DOI: 10.1016/j.ijid.2012.02.014]

57 **Horta Veloso H**, Ferreira Júnior JA, Braga de Paiva JM, Faria Honório J, Junqueira Bellei NC, Vicenzo de Paola AA. Acute atrial fibrillation during dengue hemorrhagic fever. *Braz J Infect Dis* 2003; **7**: 418-422 [PMID: 14636482 DOI: 10.1590/s1413-86702003000600010]

58 **Mahmod M**, Darul ND, Mokhtar I, Nor NM, Anshar FM, Maskon O. Atrial fibrillation as a complication of dengue hemorrhagic fever: non-self-limiting manifestation. *Int J Infect Dis* 2009; **13**: e316-e318 [PMID: 19541521 DOI: 10.1016/j.ijid.2009.01.017]

59 **Pahadiya HR**, Parmar V, Kumar H, Sagar A. Atrial Fibrillation Due to Acute Myocarditis During Dengue Haemorrhagic Fever. *J Clin Diagn Res* 2015; **9**: OL01-OL02 [PMID: 26500943 DOI: 10.7860/JCDR/2015/13375.6514]

**Footnotes**

**Conflict-of-interest statement:** The authors declare having no conflicts of interest in relation to this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** April 4, 2021

**First decision:** May 13, 2021

**Article in press:** July 7, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Thailand

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li X **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Li JH

**Figure Legends**



**Figure 1** **Viruses causing myocarditis.** HIV: Human immunodeficiency virus.

**Table 1** **Clinical presentation of the patients with acute myocarditis**

|  |  |
| --- | --- |
|  | **Clinical presentation of acute myocarditis** |
| 1 | No clinical manifestations |
| 2 | Abnormal ECG or X-ray |
| 3 | Unexplained sinus tachycardia |
| 4 | Atrial or ventricular premature beats |
| 5 | Atrial or ventricular tachycardia |
| 6 | Partial or complete heart block |
| 7 | Ventricular fibrillation/cardiac arrest |
| 8 | Acute cardiac failure |
| 9 | Circulatory collapse (shock) |

ECG: Electrocardiogram.

**Table 2** **Incidence and clinical manifestations of dengue viral infections with cardiac involvement**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Diagnosis** | **Study population** | **Incidence, %** | **Cardiac assessment methods** | **Main findings and clinical outcomes** |
| Wali *et al*[24],  1998 | DHF/DSS | 17 (14-58 yr) | 70.59 | ECG. ECHO. Radionucleotide ventriculography. Tc-99m pyrophosphate imaging | ECG showed ST and T wave changes (29.4%). Mean LVEF = 41.7%. Mean LVEF in DSS patients = 39.63% |
| Kabra *et al*[25], 1998 | DF/DHF/DSS | 54 (< 12 yr) | 16.70 | ECHO | LVEF < 50% in 16.7% of patients. LVEF < 35% in 3.7% of patients. Repeat ECHO after 2 mo showed improved LVEF |
| Khongphatthanayothin *et al*[26], 2003 | DHF | 24 (10.8 ± 2.8 yr) | - | ECHO (VCFC/ESS) | Lower LVEF, VCFC/ESS, CI, EDV and higher SVR during critical phase *vs* recovery phase |
| Kularatne *et al*[27], 2007 | DF | 120 (13-76 yr) | 62.50 | ECG. Cardiac markers | ECG abnormalities: (1) Sinus bradycardia; (2) ST-segment changes; (3) T wave changes; and (4) Right bundle branch block in 62.5% of patients; increased troponin levels in 29.4% of 17 patients |
| Khongphatthanayothin *et al*[28], 2007 | DF/DHF/DSS | 91 (5-15 yr) | 17.58 | ECHO. Cardiac markers | Reduced LVEF (< 50%) was found in 6.7%, 13.8%, and 36% of patients with DF, DHF, and DSS during the critical phase, respectively. No abnormal cardiac markers |
| Salgado *et al*[29], 2009 | DF/DHF | 102 (13 mo-10 yr) | 10.70 | ECG. ECHO | ECG: (1) sinus bradycardia in 81.8% of 11 patients; and (2) tachycardia in 18.2% of 11 patients, and T wave inversion in seven of 11 patients. ECHO: Pericardial effusions in 71.4% of 7 patients |
| La-Orkhun *et al*[30], 2011 | DF/DHF/DSS | 35 (5-15 yr) | 29.00 | ECG, 24-h Holter monitoring | During recovery phase: (1) Sinus arrhythmias; (2) First-degree AV block; (3) Mobitz type I second-degree AV block; (4) Atrial ectopic beats; and (5) Ventricular ectopic beats |
| Yacoub *et al*[18], 2012 | DF/DHF/DSS | 79 (8-46 yr) | 35.00 | ECG. ECHO. Cardiac markers | Abnormal ECG: (1) Sinus arrhythmias; (2) first-degree AV block; (3) T-wave changes; and (4) ST segment abnormalities. Systolic impairment in 45% of patients, diastolic impairment in 42%. Septal and right ventricular walls predominantly affected, worse in severe cases. 1 patient had elevated troponin I |
| Miranda *et al*[31], 2013 | DF/DHF/DSS | 81 (4 mo-81 yr) | 14.81 | Cardiac markers (troponin I and NTproBNP). ECHO. ECG. CMR | Elevated troponin I and/or NTproBNP in 14.81% of patients. 4/10 of patients had abnormal ECHO: (1) Functional abnormalities; and (2) regional wall abnormalities. 4 patients had myocardial enhancement by CMR |
| Sengupta *et al*[32], 2013 | DHF/Control | 20 (DHF) (23 ± 8 yr); 20 (control) (23 ± 5 yr) | - | ECG. ECHO | LVEF reduced in DHF compared with controls (51.25 ± 0.96% *vs* 59.32 ± 1.26%; *P* = 0.032). DHF patients had: (1) Peak longitudinal strain in subendocardial region; (2) Circumferential strain in the subepicardial region; and (3) Radial strain |
| Yadav *et al*[33], 2013 | DHF/DSS | 67 (3 mo-14 yr) | 48 (ECHO); 70 (Tei index) | ECG. ECHO. Cardiac markers | LVEF showed 48% cardiac involvement. Tei index showed 70% cardiac involvement. Tei index improved on discharge but did not normalize |
| Kirawittaya *et al*[34], 2015 | DF/DHF/DSS | 181 DF/DHF 35 Non-DF (< 15 yr) | 14.50 | ECG. ECHO. Cardiac markers | DHF patients with plasma leakage had: (1) Cardiac index (2695 *vs* 3188 L/min/m2); (2)LV myocardial performance index (0.413 *vs* 0.328); (3) **S**ystemic vascular resistance (2478 *vs* 1820 dynes.s/cm-5) compared to those without plasma leakage; and (4) Cardiac dysfunction was most pronounced around the time of plasma leakage |
| Li *et al*[35], 2016 | DHF/DSS | 1782 (adult) | 11.28 | ECG. ECHO. Cardiac markers | NSD(WS+)/SD had 46.66% myocarditis. NSD(WS-) had 9.72% myocarditis. DHF with myocarditis had longer hospitalization. Prognosis of DHF patients with and without myocarditis had no significant difference |
| Bhatt *et al*[16], 2020 | DHF/DSS | 182 (30.2 ± 12.6 yr) | 7.10 | ECG. ECHO. Cardiac markers | ECG abnormality in 44/182 (24%). Cardiac markers’ elevation in 27/182 (14.83%). ECHO abnormality in 11/182 (6.04%) |
| Bhattacharjee *et al*[36], 2020 | DF | 84 (18-65 yr) (41 cases/43 controls) | - | ECG. ECHO. Cardiac markers | CK, CK-MB, troponin T and NT-proBNP levels in cases were higher than in controls. Troponin T was positively correlated with NTproBNP |
| Cabrera-Rego *et al*[37], 2021 | DF/DHF/DSS | 427 (> 18 yr) | 19.70 | ECG. ECHO | Rhythm disorders in 16.9%. Repolarization disorders in 3.0%. Pericarditis in 1.6%. Pericardial effusion in 0.9%. Myocarditis in 0.2% |
| Shah *et al*[38],2021 | DF | 320 (> 18 yr) | 35 | ECG. ECHO. Cardiac markers | Sinus bradycardia in 19.7%. LVEF < 40% in 13.1%. Elevated troponin T in 15%. Elevated CK-MB in 10.6%. Elevated NTproBNP in 5.9%. Mortality rate was 4.38% with cardiac involvement |

AV: Arterioventricular; CI: Cardiac index CK: Creatine kinase; CMR: Cardiac magnetic resonance; DF: Dengue fever; DHF: Dengue hemorrhagic fever; DSS: Dengue shock syndrome; ECHO: Echocardiography; EDV: End-diastolic volume; ECG: Electrocardiogram; LVEF: Left ventricular ejection fraction; NSD(WS)/SD: Non-severe dengue (warning sign)/severe dengue; SVR: Sustained virological response; VCFC/ESS: Velocity of circumferential fiber shortening adjusted for end-systolic meridional wall stress.

**Table 3** **Primary histopathological features of cardiac involvement in autopsy of dengue hemorrhagic fever patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Autopsy cases, *n*** | **Gross finding**s | **Histopathological findings** |
| Bhamarapravati*et al*[15], 1967 | 100 | Focal areas of hemorrhage in the epicardium, sub endocardium, interstitial tissues, or combined | Separation of myocardial fibers with the interstitial tissue edema. Extensive hemorrhage in myocardium with condensation and acidophilic pattern of myocardial fibrils |
| Burke[39], 1968 | 12 | Petechial hemorrhage in epicardium, sub endocardium, and myocardium | No evidence of myocarditis. Normal blood vessels |
| Weerakoon *et al*[20]*,* 2011 | 5 | Evidence of florid myocarditis | Interstitial edema with inflammatory cell infiltration and necrosis of myocardial fibers. Evidence of pericarditis |
| Kularatne *et al*[40]*,* 2018 | 3 | Petechial hemorrhage | Interstitial edema with infiltration of neutrophils and lymphocytes. Lymphocytic infiltration in endomyseum |
| Marques *et al*[41]*,* 2013 | 1 | NR | Acute myocarditis with multiple areas of myocardial necrosis sur-rounded by inflammatory cellular infiltrate |
| Rathi *et al*[42],2013 | 6 | Hemorrhagic spots over pericardium, epicardium. Mild ventricular hypertrophy | Lymphocytic myocarditis |

NR: Not reported.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**